Mateon Therapeutics

Company Listings from SPi: Mateon Therapeutics

You are here: Home >> SPi Company Listings >> Mateon Therapeutics

 

Mateon Therapeutics

Website:
http://

Search for other references to "mateon" on SPi News

Latest Mateon Therapeutics News

Mateon Therapeutics Reports First Quarter 2018 Financial Results SOUTH SAN FRANCISCO, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology ind...... 12:45 GMT Monday 14th May 2018

Mateon Therapeutics Provides Business Update and Reports 2017 Financial Results SOUTH SAN FRANCISCO, Calif., April 16, 2018 (GLOBE NEWSWIRE) -- (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology i...... 21:35 GMT Monday 16th April 2018

Mateon Therapeutics Raises Net Proceeds of Approximately $2.4 Million in Financing Transaction SOUTH SAN FRANCISCO, Calif., April 16, 2018 (GLOBE NEWSWIRE) -- . (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology...... 21:10 GMT Monday 16th April 2018

Mateon Announces New Preclinical Data Demonstrating Enhanced Tumor Immune Responses when CA4P is Given in Combination with Checkpoint Inhibitors SOUTH SAN FRANCISCO, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- . (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology i...... 12:15 GMT Monday 8th January 2018

Mateon Therapeutics to Present at the 2018 Biotech Showcase SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatm...... 12:30 GMT Wednesday 3rd January 2018

Mateon Provides Corporate Update and Reports Third Quarter 2017 Financial Results SOUTH SAN FRANCISCO, Calif., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatm...... 13:00 GMT Tuesday 14th November 2017

Mateon Therapeutics Announces Updated Data from Fifth Cohort of Phase 1b Study of OXi4503 in Acute Myeloid Leukemia SOUTH SAN FRANCISCO, Calif., Oct. 30, 2017 (GLOBE NEWSWIRE) -- . (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology i...... 12:45 GMT Monday 30th October 2017

Mateon Therapeutics Announces Results from Second Interim Analysis of CA4P Phase 2/3 FOCUS Study in Platinum-resistant Ovarian Cancer SOUTH SAN FRANCISCO, Calif., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) fo...... 13:00 GMT Wednesday 16th August 2017

Mateon Therapeutics Announces New Interim Preclinical Data on CA4P in Combination with Checkpoint Inhibitors SOUTH SAN FRANCISCO, Calif., June 28, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) fo...... 12:30 GMT Wednesday 28th June 2017

Mateon Therapeutics Announces Presentations at the Tumor Microenvironment Workshop SOUTH SAN FRANCISCO, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) f...... 14:15 GMT Thursday 27th April 2017

Buy Mateon Therapeutics
Market Reports
from SPi

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us
 

Advertising on SPi News: Information For Advertisers